Table 3 Prognostic evaluation of clinicopathological parameters for cancer-specific survival in 36 cases of metastatic renal cell carcinomas by univariate and multivariate analyses
| Â | Â | Univariate | Multivariate | ||
|---|---|---|---|---|---|
|  | n | HR (95% CI) | p value†| HR (95% CI) | p value†|
Sex (male/female) | 30/6 | 2.56 (0.68–9.76) | 0.164 |  |  |
Age, years (> 62 vs ≤ 62) | 18/18 | 0.52 (0.17–1.57) | 0.247 |  |  |
Histological subtype (non-clear vs clear) | 5/31 | 0.65 (0.08–5.25) | 0.652 |  |  |
T classification (3,4 vs 1,2) | 20/16 | 2.83 (0.89–9.00) | 0.077 |  |  |
Vascular invasion (yes vs no) | 34/2 | 25.44 (0.02–44141) | 0.395 |  |  |
Pathological grade (3 vs 1,2) | 13/23 | 4.82 (1.36–17.06) | 0.015 | 1.24 (0.25–6.17) | 0.792 |
Metastasis at diagnosis (yes vs no) | 27/9 | 5.41 (1.16–25.26) | 0.032 | 6.26 (1.19–33.00) | 0.031 |
Molecular targeting therapy (yes vs no) | 25/11 | 1.33 (0.44–4.00) | 0.617 |  |  |
ARL4C expression (high vs low) | 15/21 | 4.20 (1.39–12.72) | 0.011 | 2.37 (0.52–10.51) | 0.273 |
ECT2 expression (high vs low) | 15/21 | 2.85 (0.87–9.34) | 0.084 |  |  |
SOD2 expression (high vs low) | 12/24 | 4.07 (1.28–12.94) | 0.018 | 4.97 (1.12–22.02) | 0.035 |
STEAP3 expression (high vs low) | 8/28 | 5.16 (1.56–17.08) | 0.007 | 2.19 (0.45–9.970) | 0.343 |